Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.

Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Bérez V, Borràs J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM.

J Urol. 2004 Oct;172(4 Pt 1):1256-61.

PMID:
15371818
2.

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B.

Nat Genet. 1997 May;16(1):68-73.

PMID:
9140397
3.

Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B.

Cancer Res. 1998 Apr 15;58(8):1719-22.

4.

Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.

Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S.

Int J Oncol. 2008 Aug;33(2):271-6.

PMID:
18636147
5.

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B.

Oncogene. 1999 Apr 8;18(14):2343-50.

6.

Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.

Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W.

Genet Test. 2001 Summer;5(2):101-6. Review.

PMID:
11551094
7.

Hereditary papillary renal carcinoma type I.

Dharmawardana PG, Giubellino A, Bottaro DP.

Curr Mol Med. 2004 Dec;4(8):855-68. Review.

PMID:
15579033
8.

Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma.

Prat E, Bernués M, Del Rey J, Camps J, Ponsa I, Algaba F, Egozcue J, Caballín MR, Gelabert A, Miró R.

Cancer Genet Cytogenet. 2006 Jan 15;164(2):142-7.

PMID:
16434318
9.

Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.

Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, Pak E, Pham T, Weil RJ, Candidus S, Lubensky IA, Linehan WM, Zbar B, Weirich G.

Nat Genet. 1998 Sep;20(1):66-9.

PMID:
9731534
10.

Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma.

Wadt KA, Gerdes AM, Hansen TV, Toft BG, Friis-Hansen L, Andersen MK.

Fam Cancer. 2012 Sep;11(3):535-7. doi: 10.1007/s10689-012-9542-6.

PMID:
22717761
11.

Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.

Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G.

Oncogene. 1998 Aug 13;17(6):733-9.

12.

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM, Zbar B.

Am J Pathol. 1999 Aug;155(2):517-26.

13.

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*.

Tanyi J, Tory K, Rigó J Jr, Nagy B, Papp Z.

Pathol Oncol Res. 1999;5(3):187-91.

14.

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma.

Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H.

Am J Surg Pathol. 2005 Apr;29(4):544-9.

PMID:
15767811
15.

Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.

Gatalica Z, Lilleberg SL, Vranic S, Eyzaguirre E, Orihuela E, Velagaleti G.

Hum Pathol. 2009 Dec;40(12):1813-9. doi: 10.1016/j.humpath.2009.03.026.

PMID:
19733897
16.

Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio PM, Di Renzo MF.

Int J Cancer. 1999 Aug 27;82(5):640-3.

17.

A novel germ line juxtamembrane Met mutation in human gastric cancer.

Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF.

Oncogene. 2000 Oct 12;19(43):4947-53.

18.

Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.

Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarrà G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-de Paillerets B; French Hereditary Melanoma Study Group..

Genes Chromosomes Cancer. 2001 Nov;32(3):195-202.

PMID:
11579459
19.

Biological significance of c-met over expression in papillary renal cell carcinoma.

Sweeney P, El-Naggar AK, Lin SH, Pisters LL.

J Urol. 2002 Jul;168(1):51-5.

PMID:
12050491
20.

Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.

Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B.

Proteins. 2001 Jul 1;44(1):32-43.

PMID:
11354004
Items per page

Supplemental Content

Support Center